Onc.AI
Onc.AI is a clinical-stage digital health company that builds deep-learning imaging AI models applied to CT scans to predict immunotherapy response and support oncology clinical trial decisions, serving pharmaceutical companies and oncology practices with its Onclara platform.
- Company typePrivate
- Founded2020
- HeadquartersSan Carlos, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Onc.AI does
Onc.AI is a privately held digital health company founded in 2020 and headquartered in the San Francisco Bay Area with a distributed team including a Waterloo, Ontario presence. The company develops the Onclara™ platform, a deep-learning imaging AI system that ingests standard CT scans and automatically extracts clinically relevant radiomic biomarkers—including tumor intensity, texture and morphology features, multi-site tumor burden, vascular morphology, and body composition—without manual annotation. These biomarkers feed multiple AI products: Onclara™ Evaluate (Serial CTRS) for Phase IB/II oncology clinical trial decision-making and patient stratification, Onclara™ IO for predicting immunotherapy response and 12-month overall survival in PD-L1-High metastatic non-small cell lung cancer, Lung Clinical Management (LCM) for treatment decisions, and Onclara™ Studio for cloud-based cohort and patient-level visualization.
The company operates a dual-segment enterprise model targeting pharmaceutical companies for clinical trial licensing and risk-stratification services, and healthcare systems/oncology practices for clinical decision support once FDA clearance is secured. Onclara Evaluate has received FDA Breakthrough Device Designation and a planned 510(k) submission for Onclara IO is targeted for 2027. Validation partnerships span Pfizer, GSK, and Merck on the pharma side, with Flatiron Health as a real-world data partner and clinical collaborations across Stanford Medicine, City of Hope, MD Anderson, Emory Winship, Providence Health, Baylor Scott & White, and University of Rochester Medical Center. Revenue mechanics are primarily licensing/royalty-based for pharma trial applications, with a future subscription/recurring revenue stream anticipated for clinical decision support once FDA clearance is obtained. Pricing is not publicly disclosed and all products are currently investigational.
Onc.AI has raised approximately $33 million in total funding, including a $25 million Series A in January 2023 co-led by MassMutual and Action Potential Venture Capital and a $2 million NCI SBIR grant in October 2024. The leadership team is led by founders Akshay Nanduri (CEO) and Salmaan Ahmed (VP Software), with Lester Boeh as COO and Petr Jordan, PhD as CTO. The board is chaired by Jonathan Fleming and includes clinically credentialed directors and board observers, with a scientific and clinical advisory bench spanning oncology, immunotherapy, and AI/radiomics expertise. The company remains pre-commercial as of the most recent data, with revenue not publicly disclosed.
Onc.AI firmographics
Firmographics- Name
- Onc.AI
- Legal name
- Onc.Ai, Inc.
- Website
- https://onc.ai
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Onc.AI is a clinical-stage digital health company that builds deep-learning imaging AI models applied to CT scans to predict immunotherapy response and support oncology clinical trial decisions, serving pharmaceutical companies and oncology practices with its Onclara platform.
- Ownership category
- akta.pro rank
Onc.AI industry classification
Industry- Product category
- AI-Powered Clinical Decision Support for Oncology
- NAICS
- Medical and Diagnostic Laboratories (6215), Custom Computer Programming Services (541511)
- SIC
- Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Thoracic (Lung) Oncology (HLAKAFAL)
Keywords
Where Onc.AI is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Onc.AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharma Clinical Trial Solutions: Licensing or service fees from pharmaceutical companies for Onclara Evaluate to improve clinical trial design, patient stratification, and go/no-go decision-making in Phase IB and Phase II trials
- Clinical Decision Support: Potential future revenue from healthcare systems for Onclara IO clinical decision support tools for metastatic lung cancer patients treated with immunotherapy
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Onc.AI product offering
Product offeringCore offering
Onc.AI develops and sells the Onclara™ AI platform that applies deep learning to CT imaging to extract radiomic biomarkers and predict cancer treatment outcomes. Its core products include Onclara™ Evaluate for Phase IB/Phase II clinical trial decision-making (FDA Breakthrough designated) and Onclara™ IO for predicting response and outcomes in metastatic lung cancer patients receiving immunotherapy, sold to pharmaceutical companies and healthcare systems.
Product overview
Onc.AI offers the Onclara™ platform, a unified AI-powered system for oncology decision-making comprising multiple integrated products. The platform includes Onclara™ Evaluate (FDA Breakthrough designated) for clinical trial decision-making, Onclara™ IO for immunotherapy response prediction in metastatic lung cancer, Serial CTRS for NSCLC risk classification, and Lung Clinical Management for treatment decisions. Onclara™ Studio provides cloud-based visualization and analysis tools. The products leverage deep learning applied to CT imaging to extract radiomic biomarkers, tumor burden metrics, and body composition data to generate risk stratifications and survival predictions.
Differentiator
Problem solved
Functional benefit
Brands
- Onclara™: Market-leading oncology real-world dataset platform that trains predictive and prognostic AI models for clinical decision-making in cancer treatment.
- Onclara™ Evaluate
- Onclara™ IO
- Onclara™ Studio
Products and services
- Onclara Platform Core AI platform that leverages a market-leading oncology real-world dataset to train predictive and prognostic AI models for oncology clinical trials and clinical practice; provides the infrastructure for Onclara Evaluate, Onclara IO, Serial CTRS, LCM, and Onclara Studio.
- Onclara Evaluate AI-powered clinical decision support tool that improves Phase IB/Phase II clinical trial decision-making for pharmaceutical companies; uses deep learning to identify highest-risk patients and provide calibrated probability of achieving 12-month overall survival. FDA Breakthrough Device Designated. Sold to enterprise pharma companies.
- Onclara IO AI-based CT imaging biomarker that predicts response and outcomes for metastatic lung cancer patients treated with immunotherapy; externally validated on Flatiron Health data for PD-L1-High metastatic non-small cell lung cancer. Targets healthcare systems and oncology clinical practice.
- Onclara Studio Cloud-based platform providing intuitive visual and tabular outputs for immediate review or biostatistical analysis; supports secure CT scan upload and displays cohort-level analysis (Kaplan-Meier curves), patient-level tumor burden analysis, and body composition analysis. Sold to enterprise pharma companies and clinical users.
- Serial CTRS (Serial CT Response Score) Deep learning model that classifies non-small cell lung cancer patients into risk groups; outperforms RECIST 1.1 in predicting overall survival in metastatic NSCLC patients treated with PD-1 immunotherapy. FDA Breakthrough Device Designated. Sold to pharmaceutical companies for clinical trial applications.
- Lung Clinical Management (LCM) AI-driven tool for informing treatment decision-making for metastatic lung cancer patients treated with immunotherapy; validated on Pfizer clinical trial data and real-world datasets. Targets oncologists and healthcare providers.
Quantifiable outcome
- Onclara IO High patients achieved median overall survival of 484 days vs 155 days for Onclara IO Low patients in PD-L1-High metastatic NSCLC (validated on Flatiron Health data, n=205)
- +2 more outcomes
Companies that use Onc.AI
Customer profileNamed customers11 records
Segments2 records
Ideal customer profiles2 records
Onc.AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Onc.AI partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and supporting.
- PfizercoreClinical validation partner; Onc.AI models validated on Pfizer clinical trial data including LCM validation and Serial CTRS validation on Pfizer trials; ongoing collaboration for AI-driven clinical decision support
- GSKcoreClinical validation partner; Serial CTRS validated on GSK GARNET NSCLC cohort; collaboration for clinical development of AI biomarkers in oncology
- MercksupportingPharmaceutical partner for clinical AI solutions and potential validation studies
- Flatiron HealthcoreReal-world data provider for external validation of Onc.AI models; provided retrospective cohort of 205 patients for Onclara IO validation; leading oncology data and analytics company
- University of Rochester Medical CentersupportingClinical validation partner; LCM clinical utility retrospective chart review study
- Baylor Scott & WhitesupportingClinical partner for validation studies and real-world data collaboration
- Providence HealthsupportingClinical partner for validation studies and healthcare system collaboration
- City of HopesupportingClinical partner for validation studies; comprehensive cancer center
- UT Health San Antonio MD Anderson Cancer CentersupportingClinical partner for validation studies; NCI-designated cancer center
- Emory Winship Cancer InstitutesupportingClinical partner for validation studies; NCI-designated cancer center
- Stanford MedicinesupportingClinical partner for validation studies and academic research collaboration
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Onc.AI competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Medical imaging vendor with AI-augmented CT and radiology software portfolios. Broad incumbent competitor that distributes imaging AI through its installed CT base and enterprise imaging platform.
- GE HealthCare: Global medical imaging and diagnostics incumbent with growing AI/radiomics offerings embedded in CT and PACS workflows. A broader incumbent that can bundle competing imaging AI into its installed base.
- Tempus Labs: Large oncology AI and data platform combining molecular profiling, imaging, and clinical data to support pharma R&D and clinical decision support. Broader portfolio than Onc.AI but overlaps in AI-driven oncology decision-making.
Others
- Flatiron Health (Roche): Oncology real-world data and EHR company (Roche subsidiary) and Onc.AI's external validation partner for Onclara IO. Comparable as an oncology data/AI ecosystem participant, though primarily an enabling data partner rather than a direct imaging-AI competitor.
Direct peers
- SOPHiA Genetics: AI-driven clinical decision support platform for genomic and imaging data used by hospitals and pharma. Comparable as a multimodal AI clinical decision support vendor serving both clinical practice and pharma/biotech.
- Median Technologies: Provides imaging AI and radiomics solutions for oncology clinical trials and patient management. Closely comparable as an imaging-AI vendor targeting pharma trial design and oncology decision support.
- Owkin: AI biotech company building prognostic and predictive biomarkers from real-world patient data for pharma R&D and clinical decision support across oncology. Comparable business model of AI biomarkers sold into pharma and provider workflows.
- Artera (formerly ArteraAI): Develops AI-derived biomarkers from pathology and clinical data to personalize oncology treatment decisions, including for prostate cancer. Directly comparable as an AI biomarker company selling into both pharma clinical trials and clinical decision support.
Emerging players
- PathAI: AI-powered pathology platform supporting pharma biomarker development and clinical diagnostics. Comparable AI-for-oncology business model serving pharma R&D and clinical workflows, focused on pathology rather than radiology.
- Paige.AI: AI for digital pathology in oncology, including FDA-authorized products. Comparable as an AI oncology company selling into pharma and pathology labs, but with a different primary modality (pathology vs CT imaging).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Onc.AI social profiles
Digital presenceOnc.AI compliance and trust
Trust signalCompliance1 record
Onc.AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Onc.AI leadership team
Management profileNumber of profiles
Profiles16 records
Onc.AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Onc.AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Onc.AI
What does Onc.AI do?
Onc.AI develops and sells the Onclara™ AI platform that applies deep learning to CT imaging to extract radiomic biomarkers and predict cancer treatment outcomes. Its core products include Onclara™ Evaluate for Phase IB/Phase II clinical trial decision-making (FDA Breakthrough designated) and Onclara™ IO for predicting response and outcomes in metastatic lung cancer patients receiving immunotherapy, sold to pharmaceutical companies and healthcare systems.
Is Onc.AI a public or private company?
Onc.AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Onc.AI founded?
Onc.AI was founded in 2020. It employs 11 to 50 people.
Where is Onc.AI based?
Onc.AI is headquartered in San Carlos, United States, in the North America region.
How does Onc.AI make money?
Two revenue lines are on record. Pharma Clinical Trial Solutions are the primary driver. The others are clinical Decision Support.
Who are Onc.AI's main competitors?
Broad incumbents on record are Siemens Healthineers, GE HealthCare and Tempus Labs. Flatiron Health (Roche) is listed as an others. Direct peers are SOPHiA Genetics, Median Technologies, Owkin and Artera (formerly ArteraAI). Emerging players are PathAI and Paige.AI.
Does Onc.AI have an API?
No public API is recorded for Onc.AI.
What industry is Onc.AI in?
Onc.AI's product category is AI-Powered Clinical Decision Support for Oncology. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 6215 and its SIC code is 8071.